The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.
There was an improvement in progression-free survival despite crossover.
The phase 3 CanStem111P study was terminated early due to futility.
The presence of ctDNA, both at baseline and after treatment, was associated with worse survival outcomes.
Most vaccinated patients reported having mild side effects or none at all.
Over the next 50 years, 21,604 cumulative excess cervical cancer cases are estimated in high-poverty counties.
Exkivity (mobocertinib) is approved to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Baricitinib was associated with reduced mortality.
The mean monthly number of new diagnoses of all cancer types combined fell 29.8% during the first pandemic period.
Estimated cases and deaths omitted represented 11.6% and 14.0% of cases and deaths in nursing home residents in 2020.
Long-term symptoms included shortness of breath, chronic fatigue, and neurocognitive dysfunction.
The researchers also projected an increase in cancer deaths.
The 2-year actuarial rate of local recurrence was 4.8%.
At 12 weeks, most patients had a reduction in spleen volume.